Surgical or medical treatment of obesity-associated type 2 diabetesan increasing clinical conundrum  

作　　者：Ryan J Jalleh Karen L Jones Md Shahidul Islam Lu Cai Michael Horowitz 

机构地区：[1]Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health,University of Adelaide [2]Endocrine and Metabolic Unit,Royal Adelaide Hospital,Adelaide 5000,South Australia,Australia [3]Department of Biochemistry,School of Life Sciences,University of KwaZulu-Natal,Durban 4000,KwaZulu-Natal,South Africa [4]Pediatric Research Institute,Departments of Pediatrics,Radiation Oncology,Pharmacology and Toxicology,University of Louisville,Wendy Novak Diabetes Institute,Norton Children’s Hospital,Louisville,KY 40202,United States

出　　处：《World Journal of Diabetes》2024年第10期2036-2040,共5页世界糖尿病杂志（英文）

摘　　要：In this editorial,we comment on the article by He et al,specifically in relation to the efficacy of bariatric surgery vs glucagon-like peptide-1 receptor agonist(GLP-1RA)therapy in the management of type 2 diabetes(T2D)associated with obesity.Bariatric surgery has now also been shown to be safe and effective in pre-teens and teenagers with obesity and T2D,but information on newer GLP-1RAs in these groups is predictably limited.In older individuals(age>65 years),both bariatric surgery and GLP-1RA therapy improve cardiovascular outcomes.Baria-tric surgery is not infrequently associated with post-operative postprandial hypoglycemia,which is not the case with GLP-1RAs and,paradoxically,there is evidence that GLP-1RAs may reduce both the frequency and severity of postprandial hypoglycemia.Comparative trials of the long-term efficacy of bariatric surgery and GLP-1RAs are indicated.

关 键 词：Glucagon-like peptide-1 Glucagon-like peptide-1 receptor agonist OBESITY DIABETES Weight loss Bariatric surgery Metabolic surgery HYPOGLYCEMIA 

分 类 号：R587.1[医药卫生—内分泌]